Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Immunoproteasome beta 1 inducible subunit (LMP2)
- Target
- LMP2
- Molecular classification
- Enzyme, Protease, Proteasome subunit
01
Overview
The immunoproteasome beta 1 inducible subunit (LMP2/PSMB9) is a catalytic subunit of the immunoproteasome, a specialized proteasome complex involved in generating peptides for MHC class I presentation. It is induced by inflammatory cytokines like IFN-γ and TNF-α, replacing the constitutive β1 subunit in newly formed proteasomes. This replacement alters substrate specificity, favoring the production of peptides with hydrophobic C termini suitable for MHC I binding, thereby enhancing CD8+ T cell epitope generation and adaptive immune surveillance. Inhibitors targeting β1i are under investigation for modulating immune responses in autoimmune diseases and cancer therapy.
- Other names
- PSMB9Low molecular weight protein 2β1i-subunit
02
Mechanism of action
Inhibition of proteolytic activity; modulation of antigen presentation.
03
Biological functions
Antigen processingMHC class I presentationImmune responseProtein degradation
04
Disease associations
Autoimmune diseasesCancerInflammation
05
Interacting drugs
ONX 0914
1 more in the full profile.
Beyond the preview
Go deeper on Immunoproteasome beta 1 inducible subunit (LMP2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunoproteasome beta 1 inducible subunit (LMP2).